- Home
- RLAY vs DGICA Comparison
RLAY vs DGICA Comparison
Compare RLAY & DGICA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- DGICA
- Stock Information
- Founded
- RLAY 2015
- DGICA 1986
- Country
- RLAY United States
- DGICA United States
- Employees
- RLAY N/A
- DGICA N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- DGICA Property-Casualty Insurers
- Sector
- RLAY Health Care
- DGICA Finance
- Exchange
- RLAY Nasdaq
- DGICA Nasdaq
- Market Cap
- RLAY 610.3M
- DGICA 683.3M
- IPO Year
- RLAY 2020
- DGICA N/A
- Fundamental
- Price
- RLAY $3.54
- DGICA $17.38
- Analyst Decision
- RLAY Strong Buy
- DGICA Hold
- Analyst Count
- RLAY 12
- DGICA 1
- Target Price
- RLAY $18.45
- DGICA $18.00
- AVG Volume (30 Days)
- RLAY 2.8M
- DGICA 175.4K
- Earning Date
- RLAY 08-07-2025
- DGICA 07-24-2025
- Dividend Yield
- RLAY N/A
- DGICA 4.20%
- EPS Growth
- RLAY N/A
- DGICA 965.80
- EPS
- RLAY N/A
- DGICA 2.34
- Revenue
- RLAY $8,355,000.00
- DGICA $993,644,532.00
- Revenue This Year
- RLAY $17.59
- DGICA $2.87
- Revenue Next Year
- RLAY N/A
- DGICA $4.62
- P/E Ratio
- RLAY N/A
- DGICA $7.42
- Revenue Growth
- RLAY N/A
- DGICA 3.36
- 52 Week Low
- RLAY $1.78
- DGICA $14.06
- 52 Week High
- RLAY $10.72
- DGICA $21.12
- Technical
- Relative Strength Index (RSI)
- RLAY 52.25
- DGICA 43.96
- Support Level
- RLAY $3.31
- DGICA $16.54
- Resistance Level
- RLAY $3.61
- DGICA $17.70
- Average True Range (ATR)
- RLAY 0.21
- DGICA 0.42
- MACD
- RLAY -0.02
- DGICA 0.11
- Stochastic Oscillator
- RLAY 68.67
- DGICA 68.50
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.